BeiGene is a global biotechnology company that is discovering and developing innovative oncology treatments that are more accessible and affordable to cancer patients worldwide. We have a commercial presence in more than 60 markets, with products treating various forms of cancer, and our broad and deep pipeline has the potential to address 80 percent of cancers by incidence. We have grown rapidly since our founding in 2010 to more than 10,000 colleagues working on five continents, including more than 1,100 oncology researchers, one of the largest such teams in the industry. We have administrative offices in Basel, Beijing and Cambridge, U.S. As we have grown, we have also evolved. In 2022, the company published its first Environmental, Social and Governance report and introduced “Change in the Cure,” a framework that provides a path for helping us shape a better world by advancing global health, improving access to medicines and ensuring quality in all our work. We have also introduced initiatives to improve work/life balance for our colleagues. Today, BeiGene is a 【TOP 50 Pharmaceutical Company】 and a 【TOP 20 Oncology Company】 in 2022. To learn more about BeiGene, please visit www.beigene.com or follow us on LinkedIn at @BeiGene